Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis

Open Access

Peer-reviewed

Research Article

Ning Xia,

Affiliation Department of Respiratory Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China
⨯
Hao Wang,

Affiliation Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
⨯
Xiuhong Nie

* E-mail: xiuhongnie@outlook.com

Affiliation Department of Respiratory Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China
⨯

Reader Comments (0)

Chronic obstructive pulmonary disease
Is the Subject Area "Chronic obstructive pulmonary disease" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Cardiovascular disease risk
Is the Subject Area "Cardiovascular disease risk" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Pulmonary function
Is the Subject Area "Pulmonary function" applicable to this article?

Thanks for your feedback.
Cardiovascular therapy
Is the Subject Area "Cardiovascular therapy" applicable to this article?

Thanks for your feedback.
Tachycardia
Is the Subject Area "Tachycardia" applicable to this article?

Thanks for your feedback.